Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Common Equity (2021 - 2025)

ARS Pharmaceuticals' Common Equity history spans 5 years, with the latest figure at $114.3 million for Q4 2025.

  • For Q4 2025, Common Equity fell 55.51% year-over-year to $114.3 million; the TTM value through Dec 2025 reached $114.3 million, down 55.51%, while the annual FY2025 figure was $114.3 million, 55.51% down from the prior year.
  • Common Equity for Q4 2025 was $114.3 million at ARS Pharmaceuticals, down from $147.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $368.5 million in Q1 2021 and bottomed at -$50.2 million in Q3 2022.
  • The 5-year median for Common Equity is $226.4 million (2024), against an average of $185.9 million.
  • The largest YoY upside for Common Equity was 972.7% in 2022 against a maximum downside of 115.1% in 2022.
  • A 5-year view of Common Equity shows it stood at -$31.3 million in 2021, then soared by 972.7% to $272.9 million in 2022, then decreased by 15.44% to $230.8 million in 2023, then rose by 11.28% to $256.8 million in 2024, then crashed by 55.51% to $114.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Common Equity are $114.3 million (Q4 2025), $147.7 million (Q3 2025), and $192.3 million (Q2 2025).